113. The relationship between TRIPS Agreement and CBD is an important issue in this Council. Over years, Members have conducted a lot of useful discussions on this issue. China attaches great importance to TRIPS and CBD and hopes that Members could constructively involve in this discussion presently.
114. Regarding the substantial issues, China notes that the majority of Members support to amend the TRIPS Agreement so as to ensure the mutually support of TRIPS Agreement, the CBD and its Nagoya Protocol. China believes that the introduction of a mandatory disclosure requirement, prior informed consent and the benefit sharing, could prevent the misappropriation and erroneous patents.
115. As to the issue of disclosure, China has provided the detailed suggestions on improving the transparency on genetic resources utilization, preventing the misappropriation of genetic resources and traditional knowledge, and preventing the grant of erroneous patent in two documents TN/C/W/52 and TN/C/W/59 co-sponsored by different Members.
116. China also believes the prior informed consent and benefit sharing could make better protection for the genetic resources. While the benefits arrangement on contractual basis and the database solution could not serve the purpose of sufficient protection for genetic resources.
117. As regard to procedure, China supports to invite the CBD Secretariat to brief on the Nagoya Protocol and hopes that the Secretariat could renew the three factual notes(IP/C/W/368/Rev.1, IP/C/W/369/Rev.1,IP/C/W/370/Rev.1). China believes that the discussion and negotiation in WIPO's IGC could not hinder the Members to find a solution in WTO as Ministers have given the Council the mandate to examine the relationship between TRIPS and CBD.